Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors

Strickler J.H.LoRusso P.Salgia R.Kang Y.-K.Yen C.J.CHIA-CHI LINAnsell P.Motwani M.Wong S.Yue H.Wang L.Reilly E.Afar D.Naumovski L.Ramanathan R.K.2022-09-152022-09-1520201535-7163https://www.scopus.com/inward/record.uri?eid=2-s2.0-85084272832&doi=10.1158%2f1535-7163.MCT-19-0529&partnerID=40&md5=a50e5b829b4a3f2ce91d3aa0e8d9592ehttps://scholars.lib.ntu.edu.tw/handle/123456789/620236Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumorsjournal article10.1158/1535-7163.MCT-19-0529321274662-s2.0-85084272832